Table 3 Associations between the polygenic scores and pathological diagnostic categories and variables
From: Assessment of genetic risk for improved clinical-neuropathological correlations
Pathological diagnosis | AD PHS | PD PRS | DLB PRS | |||
|---|---|---|---|---|---|---|
RRR (95% CI) | p value | RRR (95% CI) | p value | RRR (95% CI) | p value | |
MLR, control as reference | ||||||
FTD | 1.60 (1.16–2.21) | .004 | 1.01 (.60–1.70) | .97 | 1.24 (.76–2.02) | .40 |
DLB | 1.73 (1.23–2.42) | .002 | 1.39 (.80–2.41) | .24 | 3.22 (1.62–6.40) | < .001 |
AD + DLB | 3.05 (2.47–3.77) | < .001 | .93 (.67–1.28) | .65 | 4.47 (2.76–7.22) | < .001 |
AD | 3.06 (2.52–3.71) | < .001 | .92 (.69–1.22) | .57 | 3.08 (2.33–4.09) | < .001 |
AD + MTLS | 3.14 (2.45–4.02) | < .001 | .95 (.65–1.39) | .78 | 2.94 (2.07–4.18) | < .001 |
OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | |
|---|---|---|---|---|---|---|
Braak stage | ||||||
OLR, POM | – | – | 0.93 (0.82–1.05) | .24 | – | – |
OLR, PPOM | ||||||
I | 2.34 (1.60–3.42) | < .001 | – | – | 1.89 (1.06–3.39) | .03 |
II | 2.10 (1.76–2.50) | < .001 | – | – | 2.05(1.52–2.76) | < .001 |
III | 2.28 (1.99–2.62) | < .001 | – | – | 2.33 (1.88–2.89) | < .001 |
IV | 1.88 (1.68–2.10) | < .001 | – | – | 1.95 (1.63–2.33) | < .001 |
V | 1.53 (1.40–1.68) | < .001 | – | – | 1.50 (1.30–1.72) | < .001 |
VI | 1.33 (1.23–1.44) | < .001 | – | – | 1.34 (1.18–1.51) | < .001 |
Neuritic plaque density | ||||||
OLR, POM | – | – | 0.85 (0.73–0.99) | .04 | – | – |
OLR, PPOM | ||||||
Sparse | 2.69 (2.21–3.26) | < .001 | – | – | 2.79 (1.95–3.98) | < .001 |
Moderate | 2.42 (2.07–2.84) | < .001 | – | – | 2.42 (1.88–3.12) | < .001 |
Frequent | 1.71 (1.55–1.88) | < .001 | – | – | 1.63 (1.41–1.88) | < .001 |
Lewy pathology stage | ||||||
BLR | 1.03 (0.93–1.14) | .52 | 1.04 (0.87–1.24) | .66 | 1.45 (1.04–2.03) | .03 |